Nicole Buschmann

This inventor holds 13 USPTO granted patents and 1 published patent application, plus 3 CIPO patents and 6 EPO patents. Top assignee: Novartis Ag. Active years: 2011-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Nicole Buschmann. Retrieved from https://idiyas.com/inventor/nicole-buschmann

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 13 (Patent Applications = 1)

% Patents Active = 76.9

CIPO Patents = 3 (Patent Applications = 1)

EPO Patents = 6 (Patent Applications = 9)

Average Co-Inventor Count = 10.0

ph-index = 4

Forward Citations = 51(Granted Patents)

Company Filing History:

13 out of 3,978

Novartis Ag

patents

Years Active: 2011-2026

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12767647 - Glue degraders and methods of use thereof (2026-10-20),

2. 10786492 - Formylated N-heterocyclic derivatives as FGFR4 inhibitors (2020-09-29),

3. 10507201 - Use of ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors (2019-12-17),

4. 10189813 - Formylated N-heterocyclic derivatives as FGFR4 inhibitors (2019-01-29),

5. 10130629 - Pharmaceutical combinations (2018-11-20),

6. 9896449 - Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors (2018-02-20),

7. 9802917 - Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide (2017-10-31),

8. 9533988 - Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors (2017-01-03),

9. 9266883 - Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors (2016-02-23),

10. 9051279 - Substituted isoquinolinones and quinazolinones (2015-06-09),

11. 8859535 - Hydroxy substituted isoquinolinone derivatives (2014-10-14),

12. 8440693 - Substituted isoquinolinones and quinazolinones (2013-05-14),

13. 8053457 - 3-imidazolyl-indoles for the treatment of proliferative diseases (2011-11-08),

Title: The Innovative Contributions of Nicole Buschmann

Introduction

Nicole Buschmann, a distinguished inventor based in Basel, Switzerland, has made significant strides in the pharmaceutical field. With a remarkable portfolio of 12 patents, she is recognized for her innovative solutions aimed at addressing complex medical challenges through the development of novel compounds.

Latest Patents

Among her latest patents, two noteworthy inventions stand out. The first, titled "Formylated N-heterocyclic derivatives as FGFR4 inhibitors," presents a compound formula along with its pharmaceutical applications. This invention not only describes a novel compound and its manufacturing process but also outlines its therapeutic uses, showcasing the potential for impactful treatments.

The second patent, "Use of ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors," further demonstrates her expertise in creating therapeutic solutions. This patent also highlights the uses of specific compounds, emphasizing their significance in the pharmacological landscape.

Career Highlights

Nicole Buschmann's career has been largely associated with Novartis AG, a global leader in the pharmaceutical industry. Her dedication to innovation has played a crucial role in the company's mission to improve healthcare outcomes. Throughout her tenure, she has consistently contributed to research and development initiatives, positioning herself as a pivotal figure in her field.

Collaborations

In her quest for groundbreaking discoveries, Nicole has collaborated with talented professionals such as Pascal Furet and Robin Alec Fairhurst. These partnerships reflect her commitment to teamwork and the sharing of knowledge, both critical components in the fast-evolving world of biotechnology and pharmaceuticals.

Conclusion

Nicole Buschmann exemplifies the spirit of innovation through her impressive patent portfolio and dedication to research. Her contributions to FGFR4 inhibitor development highlight the significance of her work at Novartis AG and her collaborations with fellow researchers. As she continues to push the boundaries of medical science, Nicole serves as an inspiration for aspiring inventors and scientists worldwide.

Profile summary based on public USPTO records.